Psychiatry & Neurology Doctors in Osage Beach, MO Accepting Medicare

4 Psychiatry & Neurology doctors found. Showing 1 - 4

Satnam S Mahal, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 1197 Highway Kk, Osage Beach, MO 65065 Phone: 573-348-5331    Fax: 573-348-2393

Philip J Kurle, MD Psychiatry & Neurology - Neurology Medicare: May Accept Medicare Assignments Practice Location: 1075 Nichols Rd, Osage Beach, MO 65065 Phone: 573-302-3999    Fax: 573-302-2751

Dr. Cesar E Munoz, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 840 Passover Rd, Osage Beach, MO 65065 Phone: 573-302-0319    Fax: 573-693-1680

Dr. James D Dexter, M.D. Psychiatry & Neurology - Neurology Medicare: Not Enrolled in Medicare Practice Location: 54 Hospital Dr, Osage Beach, MO 65065 Phone: 573-348-8000    Fax: 573-348-8069

News Archive

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference. Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases in humans.

Researchers to develop a safer and synthetic alternative to current heparin

With a $4.6 million grant from the National Institutes of Health (under the Bioengineering Research Partnership program), research led by Rensselaer Polytechnic Institute will make its important final steps toward the development of a safer, synthetic alternative to current heparin. The researchers believe that kilogram quantities of the new drug could be developed in under five years.

FDA warns Genetech for marketing stem cell products without approval

The U.S. Food and Drug Administration has warned Genetech, Inc. of San Diego, California and its president, Edwin N. Pinos for marketing stem cell products without FDA approval and for significant deviations from current good tissue practice and current good manufacturing practice requirements, including some violations that may have led to microbial contamination, potentially causing serious blood infections in patients.

OptMed obtains FDA 510(k) marketing clearance for topical skin adhesive

OptMed Inc., a medical device manufacturer, announced today that the Company received 510(k) marketing clearance from the US Food and Drug Administration for its BondEase product, a topical skin adhesive intended for the closure of surgical incisions and lacerations as an alternative to sutures and staples.

Read more Medical News

› Verified 4 days ago